VivoSeq
Musculoskeletal

Hip Fracture

88

Pipeline Programs

18

Active Trials

42

Companies Involved

Hip Fracture is a moderately active landscape with 88 programs across 42 companies. The most active players are Novartis, GSK, Viking Therapeutics, Inc.. 34 therapies are approved with 23 more in late-stage development.

Pipeline Metrics

Competitive Density

69/100

Pipeline Velocity

25/100

Mech. Concentration

17/100

Completion Rate

67/100

Attrition Rate

21/100

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Programs by Phase

Modality Breakdown

97%

Small molecule

108 of 111 classified programs — the dominant modality here.

3%ALL OTHERSMonoclonal antibody22%Peptide1<1%

Small molecule leads; the ring shows all 111 classified programs, each share of the total. Modality classified for 99% of 117 pipeline programs.

Trial Status

118

clinical trials

Completed51 · 43%
Unknown status24 · 20%
Terminated14 · 12%
Recruiting12 · 10%
Withdrawn11 · 9%
Not yet recruiting6 · 5%

Trial Activity

118 trials

Zoledronate Early to Hip Fracture Patients - Safe and Effective?
Recruiting··Phase 4·NCT05025293·300 enrolled
Effect of Early Administration of TXA in Adult Hip Fractures
Recruiting·AAscension Health·Phase 2/3·NCT05047133·170 enrolled
HIP Fracture Oral ThromboPROphylaxis (Hip PRO Pilot)
Recruiting·UUniversity of Calgary·Phase 2·NCT05775965·250 enrolled
Page 1 of 8

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)